[DOI] [PubMed] [Google Scholar] 94.Dunn G.P., Spiliopoulos K., Plotkin S.R., Hornicek F.J., Harmon D.C., Delaney T.F., Williams Z
In einer iranischen Studie von 2011 gab man 18 untrainierten Mnnern 10 Tage lang tglich 50 mg MSM pro Kilogramm Krpergewicht oder ein Placebo
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
So, to save $300,000,000, we would lose $800,000,000 and completely destroy our dental health care infrastructure in the process
